ArticleDrug design, development and therapy2026
Remimazolam Attenuates Neurological Injury After TBI: A Potential Role of α7nAChR-Associated Mitophagy Enhancement and Pyroptosis Suppression in BV2 Cells.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Do MLA Reversal Experiments Establish α7nAChR-Dependent Neuroprotection by Remimazolam After TBI? [Letter].Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Traumatic brain injury (TBI) remains a major cause of disability and mortality worldwide. This study investigated whether remimazolam improves neurological outcomes after experimental TBI and whether these effects are associated with α7 nicotinic acetylcholine receptor (α7nAChR) related regulation of mitophagy and pyroptosis. Material and Methods: Computational analyses, LPS/ATP-stimulated BV2 cells, and a mouse model of TBI were used. Molecular docking, molecular dynamics simulations, cellular thermal shift assays, and calcium influx assays were performed to evaluate the potential interaction between remimazolam and α7nAChR. Mitochondrial function, mitophagy-related markers, NLRP3, ASC, caspase-1, and GSDMD-N were assessed in BV2 cells. Neurological and behavioral outcomes were evaluated using the modified neurological severity score, rotarod test, open-field test, and novel object recognition test, together with histopathological, inflammatory, and molecular analyses of peri-lesional brain tissue. Methyllycaconitine (MLA) and flumazenil were used to assess the involvement of α7nAChR related signaling and the classical benzodiazepine sensitive GABA_A receptor pathway. Results: Remimazolam showed a predicted interaction with α7nAChR. In vitro, it enhanced mitophagy, improved mitochondrial function, and reduced the expression of NLRP3, Caspase-1, ASC, and GSDMD-N. In vivo, remimazolam improved neurological and behavioral outcomes, attenuated histopathological brain injury and neuroinflammation, promoted mitophagy and suppressed pyroptosis. MLA and flumazenil partially attenuated these protective effects. Conclusion: Remimazolam attenuates neurological injury in experimental TBI and LPS/ATP-stimulated BV2 cells, partly through α7nAChR associated mitophagy enhancement and pyroptosis inhibition, while GABA_A receptor signaling may also be involved in these effects. These findings support its potential neuroprotective value in anesthesia and perioperative management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.